Douglas Dahl, MD

Douglas M. Dahl, MD FACS is a Urologic Surgeon at the Massachusetts General Hospital in Boston, Massachusetts. He is the Chief of Urologic Oncology. He is an Associate Professor of Urology at Harvard Medical School. His expertise is in laparoscopic and robotic surgery for prostate cancer, kidney cancer, and reconstruction of the urinary tract. He is an expert in rare malignancies of the genito-urinary organs.

Financial relationships

Attribution:
Self
Type of financial relationship:
Consultant or Advisor (General Urology)
Ineligible company:
Civco
Mitigation strategy:
Peer review
Date reviewed:
09/20/2022
Attribution:
Self
Type of financial relationship:
Investment Interest (General Urology)
Ineligible company:
Vertex
Mitigation strategy:
Peer review
Date reviewed:
09/20/2022
Attribution:
Self
Type of financial relationship:
Investment Interest (General Urology)
Ineligible company:
Tak Pharmaceuticals
Mitigation strategy:
Peer review
Date reviewed:
09/20/2022
Attribution:
Self
Type of financial relationship:
Investment Interest (Oncology)
Ineligible company:
Novartis
Mitigation strategy:
Peer review
Date reviewed:
09/20/2022
Attribution:
Self
Type of financial relationship:
Investment Interest (Specialty Not Specified)
Ineligible company:
Bristol Myers Squibb
Mitigation strategy:
Peer review
Date reviewed:
09/20/2022
Attribution:
Self
Type of financial relationship:
Investment Interest (Specialty Not Specified)
Ineligible company:
Eli Lilly
Mitigation strategy:
Peer review
Date reviewed:
09/20/2022
Attribution:
Self
Type of financial relationship:
Investment Interest (Specialty Not Specified)
Ineligible company:
Merck
Mitigation strategy:
Peer review
Date reviewed:
09/20/2022
Attribution:
Self
Type of financial relationship:
Investment Interest (Specialty Not Specified)
Ineligible company:
GlaxoSmithKline
Mitigation strategy:
Peer review
Date reviewed:
09/20/2022
Attribution:
Self
Type of financial relationship:
Investment Interest (Specialty Not Specified)
Ineligible company:
Abbvie
Mitigation strategy:
Peer review
Date reviewed:
09/20/2022
Attribution:
Self
Type of financial relationship:
Investment Interest (Specialty Not Specified)
Ineligible company:
Johnson and Johnson
Mitigation strategy:
Peer review
Date reviewed:
09/20/2022

Pages

Return to 2022 AUA Annual Meeting Highlights: Prostate Cancer